Osteoporosis in men: The role of testosterone and other sex-related factors

Current Opinion in Endocrinology and Diabetes

Volumn 12, Issue 6, 2005, Pages 452-458

  Kelly, Jennifer J ^a   Moses, Arnold M ^a,b  

^a SUNY UPSTATE MEDICAL UNIVERSITY   (United States)

^b State University of New York Upstate Medical University: College of Medicine   (United States)

Author keywords

Factors predisposing to fracture; Failure to apply knowledge to fracture prevention; Screening; Sex hormones; Vitamin D

Indexed keywords

ALENDRONIC ACID; ANABOLIC AGENT; ANDROGEN; ANTIANDROGEN; BISPHOSPHONIC ACID DERIVATIVE; CALCIFEDIOL; COLECALCIFEROL; ERGOCALCIFEROL; ESTROGEN; FINASTERIDE; GONADORELIN; PAMIDRONIC ACID; PARATHYROID HORMONE[1-34]; RISEDRONIC ACID; SEX HORMONE; TESTOSTERONE; VITAMIN D; ZOLEDRONIC ACID;

ADVERSE DRUG REACTION; ANDROGEN THERAPY; AUTOIMMUNE DISEASE; BONE DENSITY; BONE STRENGTH; BONE TURNOVER; COMPUTER ASSISTED TOMOGRAPHY; DIABETES MELLITUS; FRAGILITY FRACTURE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HIP; HIP FRACTURE; HUMAN; HYPOCALCEMIA; HYPOGONADISM; MASS SPECTROMETRY; MUSCLE STRENGTH; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEOMALACIA; OSTEOPOROSIS; PREVALENCE; PROSTATE CANCER; REVIEW; RICKETS; SCREENING TEST; SKELETON; SPINE; TRABECULAR BONE; ULTRAVIOLET IRRADIATION; VERTEBRA FRACTURE; VITAMIN D DEFICIENCY;

EID: 29544437468     PISSN: 10683097     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.med.0000184293.92198.90     Document Type: Review

References (80)

1. Kanis JA, Johnell O, Oden A, et al. Epidemiology of osteoporosis and fracture in men. Calcif Tissue Int 2004; 75:90-99.
2. Bilezikian JP. Commentary: osteoporosis in men. J Clin Endocrinol Metab 1999; 84:3431-3434.
3. Melton LJ III, Chrischilles EA, Cooper C, et al. How many women have osteoporosis? J Bone Miner Res 1992; 7:1005-1010.
4. Cooper C, Melton LJ III. Epidemiology of osteoporosis. Trends Endocrinol Metab 1992; 3:224-229.
5. Seeman E. During aging, men lose less bone than women because they gain more periosteal bone, not because they resorb less endosteal bone. Calcif Tissue Int 2001; 69:205-208.
6. Diamond TH, Thornley SW, Sekel R, Smerdely P. Hip fracture in elderly men: prognostic factors and outcomes. Med J Aust 1997; 167:412-415.
7. Forsen L, Sogaard AJ, Meyer HE, et al. Survival after hip fracture: short and long-term excess mortality according to age and gender. Osteoporos Int 1999; 10:73-78.
8. Farmer ME, White LR, Brody JA, Bailey KR. Race and sex difference in hip fracture incidence. Am J Public Health 1984; 74:1374-1380.
9. Center JR, Nguyen TV, Schneider D, et al. Mortality after all types of osteoporotic fractures in men and women: an observational study. Lancet 1999; 353:878-882.
10. Seeman E, Bianchi G, Adami S, et al. Osteoporosis in men - consensus is premature. Calcif Tissue Int 2004; 75:120-122. Succinct summary by authorities in the field addressing the major points from the second international conference on osteoporosis in men held in April 2003 in Genoa, Italy. The review addresses epidemiology, bone structural differences between the sexes, proper use of T-scores in men, androgen deficiency, and treatment.
11. Nieves JW, Formica C, Ruffing J, et al. Males have larger skeletal size and bone mass than females, despite comparable body size. J Bone Miner Res 2005; 20:529-535.
12. Seeman E. The growth and age-related origins of bone fragility in men. Calcif Tissue Int 2004; 75:100-109.
13. Peacock M, Koller DL, Fishburn T, et al. Sex-specific and non-sex-specific quantitative trait loci contribute to normal variation in bone mineral density in men. J Clin Endocrinol Metab 2005; 90:3060-3066.
14. Jackson JA, Kleerekoper M, Parfitt AM, et al. Frame B: bone histomorphometry in hypogonadal and eugonadal men with spinal osteoporosis. J Clin Endocrinol Metab 1987; 65:53-58.
15. Khosla S, Melton LJ III, Riggs BL. Estrogens and bone health in men. Calcif Tissue Int 2001; 69:189-192.
16. Orwoll ES. Treatment of osteoporosis in men. Calcif Tissue Int 2004; 75:114-119.
17. Szulc P, Munoz F, Claustrat B, et al. Bioavailable estradiol may be an important determinant of osteoporosis in men: the MINOS study. J Clin Endocrinol Metab 2001; 86:192-199.
18. Khosla S, Melton LJ III, Robb RA, et al. Relationship of volumetric BMD and structural parameters at different skeletal sites to sex steroid levels in men. J Bone Miner Res 2005; 20:730-740. Well-designed study assessing volumetric BMD and geometry in an age-stratified population sample of men. The limitations of dual X-ray absorptiometry (DXA) and the utility of QCT with the role of bioavailable estrogen are highlighted.
19. Orwoll ES. Androgens: basic biology and clinical implication. Calcif Tissue Int 2001; 69:185-188.
20. Boullion R, Bex M, Vanderschueren D, Boonen S. Estrogens are essential for male pubertal periosteal bone expansion. J Clin Endocrinol Metab 2004; 89:6025-6029.
21. Francis RM. Androgen replacement in aging men. Calcif Tissue Int 2001; 69:235-238.
22. Snyder PJ, Peachey H, Hannoush P, et al. Effect of testosterone treatment on bone mineral density in men over 65 years of age. J Clin Endocrinol Metab 1999; 84:1966-1972.
23. Snyder PJ. Effects of age on testicular function and consequences of testosterone treatment. J Clin Endocrinol Metab 2001; 86:2369-2372.
24. Liu PY, Swerdloff RS, Veldhuis JD. The rationale, efficacy and safety of androgen therapy in older men: future research and current practice recommendations. J Clin Endocrinol Metab 2004; 89:4789-4796. Excellent summary of current thoughts on androgen replacement in men. Includes a user-friendly algorithm for the assessment and work up of male hypogonadism.
25. Snyder PJ. Hypogonadism in elderly men - what to do until the evidence comes. N Engl J Med 2004; 350:440-442.
26. Amory JK, Watts NB, Easley KA, et al. Exogenous testosterone or testosterone with finasteride increases bone mineral density in older men with low serum testosterone. J Clin Endocrinol Metab 2004; 89:503-510. A unique study on the effects of testosterone replacement on BMD in older, hypogonadal men. Finasteride was administered along with testosterone in one arm of the study to assess for a protective effect on the prostate. This study was recognized and awarded by the Endocrine Society.
27. Barrett-Conner E, Bhasin S. Editorial: time for (more research on) testosterone. J Clin Endocrinol Metab 2004; 89:501-502.
28. Behre HM, Kliesch S, Leifke E, et al. Long-term effect of testosterone therapy on bone mineral density in hypogonadal men. J Clin Endocrinol Metab 1997; 82:2386-2390.
29. Schubert M, Bullmann C, Minnemann T, et al. Osteoporosis in male hypogonadism: responses to androgen substitution differ among men with primary and secondary hypogonadism. Horm Res 2003; 60:21-28.
30. Olofsson H, Byberg L, Mohsen R, et al. Smoking and the risk of fracture in older men. J Bone Miner Res 2005; 20:1261-1263. Tobacco smoking significantly increases fracture risk in older men. Smoking was shown to be a stronger, dose-dependent, and more lasting risk factor than previously thought.
31. McCabe LD, Martin BR, McCabe GP, et al. Dairy intakes affect bone density in the elderly. Am J Clin Nutr 2004; 80:1066-1074.
32. Nordstrom A, Karlsson C, Nyquist F, et al. Bone loss and fracture risk after reduced physical activity. J Bone Miner Res 2005; 90:202-207.
33. Ensrud KE, Fullman RL, Barrett-Connor E, et al. Voluntary weight reduction in older men increases hip bone loss: the Osteoporotic Fractures in Men Study. J Clin Endocrinol Metab 2005; 90:1998-2004.
34. Bischoff HA, Stahelin HB, Dick W, et al. Effects of vitamin D and calcium supplementation on falls, a randomized controlled trial. J Bone Miner Res 2003; 18:343-351.
35. Holick MF. Sunlight and vitamin D for bone health and prevention of autoimmune diseases, cancers, and cardiovascular disease. Am J Clin Nutr 2004; 80(Suppl):1678S-1688S.
36. Bischoll-Ferrari HA, Willett WC, Wong JB, et al. Fracture prevention with vitamin D supplementation: a metaanalysis of randomized controlled trials. JAMA 2005; 293:2257-2264.
37. Hollis BW, Wagner CL Normal serum vitamin D levels. N Engl J Med 2005; 352:515-516.
38. Heaney RP. Functional indices of vitamin D status and ramifications of vitamin D deficiency. Am J Clin Nutr 2004; 80(Suppl):1706S-1709S.
39. Dawson-Hughes B, Heaney RP, Holick MF, et al. Estimates of optimal vitamin D status. Osteoporos Int 2005; 16:713-716. This article was written by six acknowledged experts in vitamin D research. It presents a summary of the authors' opinion about the minimal levels of 25-hydroxyvitamin D required to maximize intestinal calcium absorption, and the amount of oral cholecalciferol required daily to attain this level.
40. Boling EP. Gender and osteoporosis: similarities and sex-specific differences. J Gend Specif Med 2001; 4:36-43.
41. Szulc P, Beck TJ, Marchand F, Delmas PD. Low skeletal muscle mass is associated with poor structural parameters of bone and impaired balance in elderly men - the MINOS study. J Bone Miner Res 2005; 20:721-729.
42. Janessen HCJP, Samson MM, Verhaar HJJ. Vitamin D deficiency, muscle function, and falls in elderly people. Am J Clin Nutr 2002; 75:611-615.
43. Bhasin S, Woodhouse L, Casaburi R, et al. Older men are as responsive as young men to the anabolic effects of graded doses of testosterone on the skeletal muscle. J Clin Endocrinol Metab 2005; 90:678-688.
44. Smith MR, McGovern FJ, Zietman AL, et al. Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl J Med 2001; 345:948-955.
45. van der Poest CE, van Engeland M, Ader H, et al. Alendronate in the prevention of bone loss after a fracture of the lower leg. J Bone Miner Res 2002; 17:2247-2255.
46. Zehnder Y, Risi S, Knecht H, et al. Prevention of bone loss in paraplegics over 2 years with alendronate. J Bone Miner Res 2004; 1067-1074.
47. Campion JM, Maricic MJ. Osteoporosis in men. Am Fam Physician 2003; 67:1521-1526.
48. Kemmis K, Stuber D. Diabetes and osteoporotic fractures: the diabetes educator's role in screening, evaluating, treating, and referring. Todays Educ 2005; 31:187-196.
49. Schwartz AV, Sellmeyer DE, Strotmeyer ES, et al. Diabetes and bone loss at the hip in older black and white adults. J Bone Miner Res 2005; 20:596-603.
50. DeLaet CEDH, Van Hout BA, Burger H, et al. Hip fracture prediction in elderly men and women: validation in the Rotterdam Study. J Bone Miner Res 1998; 13:1587-1593.
51. DeLaet CEDH, Van Der Klift M, Hofman A, Pols HAP. Osteoporosis in men and women: a story about bone mineral density thresholds and hip fracture risk. J Bone Miner Res 2002; 17:2231-2236.
52. Leib ES, Lewiecki EM, Binkley N, Hamdy RC. Official positions of the International Society for Clinical Densitometry. J Clin Densitom 2004; 7:1-5.
53. Mittan D, Lee S, Miller E, et al. Bone loss following hypogonadism in men with prostate cancer treated with GnRH analogs. J Clin Endocrinol Metab 2002; 87:3656-3661.
54. Stoch SA, Parker RA, Chen L, et al. Bone loss in men with prostate cancer treated with gonadotropin-releasing hormone agonists. J Clin Endocrinol Metab 2001; 86:2787-2791.
55. Daniell HW. Osteoporosis due to androgen deprivation therapy in men with prostate cancer. Urology 2001; 58:101-107.
56. Shahinian V, Kuo YF, Freeman JL, Goodwin JS. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 2005; 352:154-164.
57. Lopez AM, Pena MA, Hernandez R, et al. Fracture risk in patients with prostate cancer on androgen deprivation therapy. Osteoporos Int 2005; 16:707-711.
58. Nishiyama T, Ishizaki F, Anraku T, et al. the influence of androgen deprivation therapy on metabolism in patients with prostate cancer. J Clin Endocrinol Metab 2005; 90:657-660.
59. Agha A, Rogers B, Sherlock M, et al. Anterior pituitary dysfunction in survivors of traumatic brain injury. J Clin Endocrinol Metab 2004; 89:4929-4936.
60. Olszynski WP, Davison KS, Adachi JD, et al. Osteoporosis in men: epidemiology, diagnosis, prevention, and treatment. Clin Ther 2004; 26:15-28. A comprehensive and up-to-date review of the different facets of osteoporosis in men.
61. Armas LA, Hollis BW, Heaney RP. Vitamin D2 is much less effective than vitamin D3 in humans. J Clin Endocrinol Metab 2004; 89:5387-5391. Informative study that demonstrates the greater potency of cholecalciferol over ergocalciferol.
62. Binkley N, Drueger D, Cowgill CS, et al. Assay variation confounds the diagnosis of hypovitaminosis D: a call for standardization. J Clin Endocrinol Metab 2004; 89:3152-3157.
63. Sawka AM, Thabane L, Papaioannou A, et al. A systematic review of the effect of alendronate on bone mineral density in men. J Clin Densitom 2005; 8:7-13.
64. Shimon I, Eshed V, Doolman R, et al. Alendronate for osteoporosis in men with androgen-repleted hypogonadism. Osteoporos Int 2005; in press
65. Ringe JD, Dorst A, Faber H, Ibach K. Alendronate treatment of established primary osteoporosis in men: 3-year results of a prospective, comparative, two-arm study. Rheumatol Int 2004; 24:110-113.
66. Gonnelli S, Cepollaro C, Montagnani A, et al. Alendronate treatment in men with primary osteoporosis: a three-year longitudinal study. Calcif Tissue Int 2003; 73:133-139.
67. Ringe JD, Orwoll E, Daifotis A, Lombardi A. Treatment of male osteoporosis: recent advances with alendronate. Osteoporos Int 2002; 13:195-199.
68. Orwoll E, Ettinger M, Weiss S, et al. alendronate for the treatment of osteoporosis in men. N Engl J Med 2000; 343:604-610.
69. Ringe JD, Faber H, Farahmand P, Dorst A. Efficacy of risedronate in men with primary and secondary osteoporosis: results of a 1-year study. Rheumatol Int 2005; 7:1-5.
70. Kaufman JM, Orwoll E, Goemaere S, et al. Teriparatide effects on vertebral fractures and bone mineral density in men with osteoporosis: treatment and discontinuation of therapy. Osteoporos Int 2004; 16:510-516. An informative study, the first to show that teriparatide treatment can reduce the risk of moderate and severe vertebral fractures in men with idiopathic and hypogonadal osteoporosis.
71. Orwoll ES, Scheele WH, Paul S, et al. The effect of teriparatide (human parathyroid hormone [1-34]) therapy on bone density in men with osteoporosis. J Bone Miner Res 2003; 18:9-17.
72. Kurland ES, Cosman F, McMahon DJ, et al. Parathyroid hormone as a therapy for idiopathic osteoporosis in men: effects on bone mineral density and bone markers. J Clin Endocrinol Metab 2000; 85:3069-3076.
73. Finkelstein JS, Hayes A, Hunzelman JL, et al. The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N Engl J Med 2003; 349:1216-1226.
74. Lim GC, Moses AM. Resistance to the action of vitamin D in mother and daughter with asymptomatic celiac disease [abstract]. Program of the 87th Annual Meeting of the Endocrine Society, San Diego, June 2005. Abstract P2-599.
75. Kuehn BM. Longer-lasting osteoporosis drugs sought. JAMA 2005; 293:2458.
76. Vermeulen A. Androgen replacement therapy in the aging male - a critical evaluation. J Clin Endocrinol Metab 2001; 86:2380-2390.
77. Rosen CJ, Bilezikian JP. Clinical review 123: hot topic anabolic therapy for osteoporosis. J Clin Endocrinol Metab 2001; 86:957-964.
78. Miller PD, Bilezikian JP, Deal C, et al. clinical use of the teriparatide in the real world: initial insights. Endocr Pract 2004; 2:139-148.
79. Epstein S. The roles of bone mineral density, bone turnover, and other properties in reducing fracture risk during antiresorptive therapy. Mayo Clin Proc 2005; 80:379-388. An important review of the different aspects to be considered in the reduction of fractures in osteoporosis. This article discusses factors beyond bone density that contribute to the quality and strength of bone, particularly the available evidence on assessing these properties for treatment with antiresorptive medications.
80. Felsenberg D, Boonen S. The bone quality framework: determinants of bone strength and their interrelationships, and implications for osteoporosis management. Clin Ther 2005; 27:1-11. An examination of the determinants of bone strength and how an understanding of this concept can improve assessment of fracture risk.